PolarityTE
About PolarityTE
PolarityTE, Inc. is a regenerative medicine company positioned to be the first to successfully regenerate human skin.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Denver Lough
PRODUCTS:
All Products
FOLLOW POLARITYTE:
Tweets by PolarityTE
153 articles about PolarityTE
-
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication
1/18/2022
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers.
-
PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
12/20/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it has submitted its complete response to the U.S. Food and Drug Administration's (FDA) clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE® with a proposed indication for chronic cutaneous ulcers.
-
PolarityTE Reports Third Quarter 2021 Financial Results and Provides Business Update
11/10/2021
PolarityTE, Inc. a biotechnology company developing regenerative tissue products and biomaterials, provided a business update and reported financial results for the three and nine-month periods ended September 30, 2021.
-
PolarityTE to Report Third Quarter Financial Results on November 10, 2021
10/28/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended September 30, 2021 by press release on Wednesday, November 10, 2021 at approximately 7:00 a.m. Eastern Time .
-
PolarityTE Provides Update on Investigational New Drug Application
10/7/2021
PolarityTE, Inc. today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers submitted to the Food and Drug Administration (FDA) in July 2021
-
PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare Conference
9/7/2021
PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare Conference
-
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®
8/24/2021
PolarityTE, Inc. today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE ® with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021.
-
PolarityTE Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
PolarityTE, Inc., a biotechnology company developing regenerative tissue products and biomaterials, provided a business update and reported financial results for the second quarter ended June 30, 2021.
-
PolarityTE to Report Second Quarter Financial Results on August 12, 2021
7/29/2021
PolarityTE, Inc. announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approximately 4:00 p.m. Eastern Time.
-
SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial
7/28/2021
PolarityTE, Inc. announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with its investigational product SkinTE® plus standard of care vs SOC alone.
-
PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers
7/26/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers.
-
PolarityTE Issues Statement About Potential Ticker Symbol Confusion
7/16/2021
Based on investor inquiries, it has been brought to the attention of PolarityTE that there may be confusion amongst the investment community related to PolarityTE’s stock and Peet DeFi, which is a crypto currency asset, and the Company is concerned that such confusion may have affected trading in PolarityTE stock.
-
PolarityTE Receives Notice of Allowance for Chinese Patent
7/12/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3.
-
PolarityTE Reports First Quarter Results and Provides Business Update
5/13/2021
PolarityTE, Inc., a biotechnology company developing regenerative tissue products and biomaterials, provided a business update and reported financial results for the first quarter ended March 31, 2021.
-
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint
5/10/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced preliminary topline data demonstrating that a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881254) met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) at 12 weeks
-
PolarityTE to Report First Quarter Financial Results on May 13, 2021
5/3/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time. I
-
PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results
3/30/2021
Fourth Quarter Revenues of $3.59 million and Full Year 2020 Revenues of $10.13 million PolarityTE to host conference call and webcast today, March 30, 2021 at 8:00 a.m. ET
-
PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021
3/10/2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2020 by press release on Tuesday, March 30, 2021 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on March 30, 2021 at 8:00 a.m. Eastern Time.
-
PolarityTE Provides Corporate Update
2/10/2021
PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareholder value by pursuing pre-market approval for SkinTE® from the U.S. Food and Drug Administration (FDA) through submission of an investigational new drug application (IND) and eventual biologics license application (BLA),
-
PolarityTE Receives Allowance for Additional U.S. Patent
2/3/2021
PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/165,169 filed on October 19, 2018.